About Asher Biotherapeutics
Asher Biotherapeutics is a company based in San Francisco (United States) founded in 2019 by Andy Yeung and Ivana Djuretic.. Asher Biotherapeutics has raised $218.49 million across 4 funding rounds from investors including ARE, Astrazeneca and Marshall Wace. Asher Biotherapeutics offers products and services including Etakafusp alfa, AB821, and AB359. Asher Biotherapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
- Founders Andy Yeung, Ivana Djuretic
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Asher Biotherapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$218.49 M (USD)
in 4 rounds
-
Latest Funding Round
$55 M (USD), Series C
Apr 03, 2024
-
Investors
ARE
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Asher Biotherapeutics
Asher Biotherapeutics offers a comprehensive portfolio of products and services, including Etakafusp alfa, AB821, and AB359. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cis-targeted IL-2 for activating CD8+ T cells in cancer therapy.
Cis-targeted therapy for augmenting cell therapies in oncology.
Cis-targeted cytokine for enhancing immune cell responses.
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Scientific Team
7 people
Founder Team
1 people
Consultant Team
1 people
Unlock access to complete
Funding Insights of Asher Biotherapeutics
Asher Biotherapeutics has successfully raised a total of $218.49M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $55.0M
-
First Round
First Round
(19 Aug 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series C - Asher Biotherapeutics | Valuation | RA Capital Management | |
| Sep, 2021 | Amount | Series B - Asher Biotherapeutics | Valuation | Wellington | |
| Mar, 2021 | Amount | Series A - Asher Biotherapeutics | Valuation | Third Rock Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Asher Biotherapeutics
Asher Biotherapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Astrazeneca and Marshall Wace. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Asher Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Asher Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Asher Biotherapeutics Comparisons
Competitors of Asher Biotherapeutics
Asher Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Asher Biotherapeutics
Frequently Asked Questions about Asher Biotherapeutics
When was Asher Biotherapeutics founded?
Asher Biotherapeutics was founded in 2019.
Where is Asher Biotherapeutics located?
Asher Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Asher Biotherapeutics?
Craig Gibbs is the current CEO of Asher Biotherapeutics.
Is Asher Biotherapeutics a funded company?
Asher Biotherapeutics is a funded company, having raised a total of $218.49M across 4 funding rounds to date. The company's 1st funding round was a Series A of $55M, raised on Aug 19, 2019.
What does Asher Biotherapeutics do?
Asher Biotherapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. CIS-targeted immunotherapies are developed to activate specific immune cell types for treating cancer and autoimmune diseases. The pipeline features AB248, aimed at cancer and infectious diseases, alongside treg cis-targeted IL-2 for autoimmune conditions. Operations focus on improving therapeutic outcomes through immune modulation.
Who are the top competitors of Asher Biotherapeutics?
Asher Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Asher Biotherapeutics offer?
Asher Biotherapeutics offers Etakafusp alfa, AB821, and AB359.
Who are Asher Biotherapeutics's investors?
Asher Biotherapeutics has 14 investors. Key investors include ARE, Astrazeneca, Marshall Wace, Janus Henderson Investors, and RA Capital.